RCA
MRNA icon

Riverview Capital Advisers’s Moderna MRNA Stock Holding History

Riverview Capital Advisers’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,170
Closed -$534K – 84
2023
Q3 		$534K Sell
5,170
-737
-12% -$82.2K 0.24% 63
2023
Q2 		$718K Sell
5,907
-4,143
-41% -$553K 0.32% 58
2023
Q1 		$1.54M Buy
10,050
+50
+0.5% +$8.25K 0.66% 35
2022
Q4 		$1.8M Sell
10,000
-50
-0.5% -$8.18K 0.96% 27
2022
Q3 		$1.19M Buy
10,050
+50
+0.5% +$7.59K 0.75% 38
2022
Q2 		$1.43M Hold
10,000
– – 0.79% 36
2022
Q1 		$1.72M Sell
10,000
-50
-0.5% -$8.42K 0.79% 35
2021
Q4 		$2.55M Buy
+10,050
New +$2.94M 1.14% 27

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Riverview Capital Advisers's MRNA Position: Q4 2023 in Review

Riverview Capital Advisers sold out of Moderna (MRNA) in Q4 2023, closing a stake of 5,170 shares — an estimated $534K sold.

Riverview Capital Advisers first reported a position in MRNA in Q4 2021 and held it in 8 quarters. The position peaked at $2.55M in Q4 2021. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Riverview Capital Advisers reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Riverview Capital Advisers sold 5,170 Moderna shares in Q4 2023, an estimated $534K.
  • Riverview Capital Advisers first reported a position in Moderna in Q4 2021 and held it in 8 quarters.
  • Riverview Capital Advisers's Moderna position peaked at $2.55M in Q4 2021.
  • 884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Riverview Capital Advisers's 13F filing for Q4 2023, filed 12 Feb 2024.